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Abstract 
The mechanisms underlying discrimination between “self” and “non‑self”, a central immunological principle, require 
careful consideration in immune oncology therapeutics where eliciting anti‑cancer immunity must be weighed 
against the risk of autoimmunity due to the self origin of tumors. Whole cell vaccines are one promising immuno‑
therapeutic avenue whereby a myriad of tumor antigens are introduced in an immunogenic context with the aim of 
eliciting tumor rejection. Despite the possibility collateral damage to healthy tissues, cancer immunotherapy can be 
designed such that off target autoimmunity remains limited in scope and severity or completely non‑existent. Here 
we provide an immunological basis for reconciling the safety of cancer vaccines, focusing on tumor endothelial cell 
vaccines, by discussing the following topics: (a) Antigenic differences between neoplastic and healthy tissues that 
can be leveraged in cancer vaccine design; (b) The layers of tolerance that control T cell responses directed against 
antigens expressed in healthy tissues and tumors; and, (c) The hierarchy of antigenic epitope selection and display 
in response to whole cell vaccines, and how antigen processing and presentation can afford a degree of selectivity 
against tumors. We conclude with an example of early clinical data utilizing ValloVax™, an immunogenic placental 
endothelial cell vaccine that is being advanced to target the tumor endothelium of diverse cancers, and we report on 
the safety and efficacy of ValloVax™ for inducing immunity against tumor endothelial antigens.
© 2016 Wagner et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Leveraging the antigenic identity of tumors
The clinical possibility of manipulating the immune sys-
tem to eradicate cancer originated in early work of Wil-
liam Coley who demonstrated tumor regression in soft 
tissue sarcoma patients treated with bacterial extracts in 
the early 1900s [1]. Based on observations that immune 
stimulation can be associated with spontaneous regres-
sion of cancer, numerous antigen-non-specific immu-
notherapy approaches have been introduced that are 
directed against cell-surface molecules, receptors, and 
immune effector pathways including Bacillus Calmette–
Guérin (BCG), interleukin-2 (IL-2), interferons, CpG 
oligonucleotides, enzyme inhibitors targeting immune 
regulatory pathways, and antibodies against receptors 
involved in immune tolerance such as anti-CTLA-4 and 
anti-PD-1/PD-1 ligand antibodies [2]. Notably, these tac-
tics for imparting generalized immune stimulation are 
capable of benefiting both innate and/or cell mediated 
components of anti-tumor immunity.
As knowledge concerning the exquisite specificity 
of the immune system has advanced, antigen-specific 
therapies are also being advanced to afford a degree of 
selectivity toward cancer cells. A groundbreaking area of 
immunotherapy has been the identification of antigens 
expressed by tumor cells and the epitopes thereof that 
elicit anti-tumor CD4+ and CD8+ responses. This line 
of investigation has revolutionized the field of immuno-
therapy through numerous breakthroughs including the 
following: (a) FDA approval for therapy with pre-primed 
antigen presenting cells (Provenge®) using a prostate can-
cer patient’s own dendritic cells to present a tumor anti-
gen; (b) Immune checkpoint inhibitors designed to turn 
off inhibitory signals in the immune system and unmask 
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nivolumab, pembrolizumab); and, (c) Promising results 
with genetically engineered chimeric antigen receptor 
(CAR)-T cells for addressing solid tumors. As will be 
described in more detail, the success of these strategies in 
terms of their immunogenicity against tumors was tem-
pered with an element of caution owing to the complex 
relationship that exists between tumor immunity and 
autoimmunity.
The antigenic composition of tumors as well as tumor 
stromal and endothelial elements, and how this infor-
mation can be utilized for vaccine design continues to 
be examined. These tumor-expressed antigens can be 
classed into several major categories that are not mutu-
ally exclusive [3]: (1) Over-expressed self-antigens found 
in both normal and neoplastic tissue; (2) Mutated tumor-
specific antigens due to genetic mutations or alterations 
in transcription, or post-translationally modified antigens 
expressing; (3) Oncoviral antigens encoded by tumo-
rigenic transforming viruses; (4) Oncofetal antigens that 
are normally only expressed during development and 
not in healthy adult tissues; (5) Lineage-specific anti-
gens expressed by a particular tumor histotype; (6) Can-
cer testis antigens that are normally expressed by male 
germ cells and placental trophoblast; and, (7) Idiotypic 
antigens where the tumor expresses a specific clono-
type, as occurs in leukemia and lymphoma. Significantly, 
tumor-specific antigens such as oncoviral antigens and 
mutated self-antigens have only been identified in some 
types of cancers, and the best-characterized targets of 
immunotherapy are the over-expressed self-antigens that 
may expressed at some level by non-malignant cells [4]. 
Indeed, T cells and antibodies from cancer patients rec-
ognize primarily tumor antigens shared in common with 
other self-tissues.
While knowing the composition of the tumor proteome 
is informative but these molecular criteria do not define 
the importance of individual tumor antigens as targets of 
therapy. Few tumor antigens are causal to the disease pro-
cess and many are also not indispensable for cancer growth 
due to the array of redundant pathways that can be evoked 
for tumor growth, angiogenesis, and survival. Therefore, 
antigens that are useful as immunotherapeutic candidates 
must meet the criteria of encoding epitopes that are pro-
cessed and presented to tumor-reactive CD4+ and CD8+ 
T cells and, furthermore, must invoke clinically beneficial 
responses (i.e. breaking tumor tolerance) without deleteri-
ous autoimmunity against healthy tissues [5].
Hand in hand with their varying degree of “self ” iden-
tity, there are also theoretical differences in the ease with 
which T cell tolerance to these different categories of 
antigens can be overcome. On one end of the spectrum 
are antigens that are tumor-specific but are not found 
in normal tissue, for example, mutated oncogenes that 
could provide novel epitopes for T cell activation [5]. 
Owing to the fact that these antigens are not expected 
to trigger peripheral tolerance, the immunogenicity 
of these antigens is high and the risk of autoimmun-
ity is low. Unfortunately, these antigens are not readily 
identifiable and are generally patient- or tumor type-
specific. On the other hand, tumors contain a prepon-
derance of antigens shared between tumor and normal 
tissues, which may evoke partial tolerance and activate 
low to intermediate affinity T cells. In this case, immu-
nogenicity is lower; however, the theoretical risk for 
autoimmunity is greater [5]. Notably, peripheral toler-
ance against self-antigens is an imperfect process. High 
avidity T cells that respond to physiological quantities of 
a particular antigen are effectively deleted [5]. However, 
“self-ignorant” T cells that do not see their specific self-
antigen in sufficient quantities or lower affinity T cells 
under normal conditions are often not eliminated and 
can persist in the periphery. The immunological play-
ers are thus in place for successful tumor vaccination; 
specifically, abundant self-antigen expression in tumors, 
and autoreactive T cells directed against these putative 
tumor rejection antigens.
Degrees of “self” identity and tolerance thresholds 
to tumor antigen
Since tumors are essentially self-entities that possess 
the gamut of antigens from their tissue of origin, there 
are numerous layers of tolerance that immunotherapy 
must overcome. Soluble immunosuppressive media-
tors, including transforming growth factor beta and 
indolamine 2,3-dioxygenase (IDO), immune regulatory 
cells, receptor/ligand expression on tumor cells such as 
CTLA-4 and PD-1/PD-1L and tumor-derived exosomes 
all serve to dampen T cell activity (reviewed in [6]). In 
addition to the tumors themselves, the tumor vasculature 
is a promising immunotherapeutic target where factors 
such as hypoxia and over-expression of growth factor 
results in dysfunctional endothelial cells that are essen-
tial for tumor growth and survival [7]. Tumor endothe-
lial cells express the death mediator Fas ligand, leading 
to loss of effector CD8+ T cells and a preponderance of 
tolerogenic regulatory T cells infiltrating into tumors [8]. 
Moreover, the tumor milieu contains an excess of vas-
cular endothelial growth factor (specifically, VEGF-C, 
a lympho-angiogenic factor) that promotes apoptosis of 
tumor-specific CD8+ T cells in an animal model [9]. In 
a study of human cancer cell lines, VEGF was shown to 
prevent the maturation of dendritic cells, which is neces-
sary for anti-tumor T cell activation [10]. If these barriers 
to T cell immunity can be overcome, anti-angiogenesis 
therapy is a powerful immunotherapy approach whereby 
it is conceptually possible for hundreds of tumor cells to 
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be starved by knocking down a single tumor endothelial 
cell [11].
A model has been put forth that, for a given antigen, 
there is a critical threshold of immunity that must be 
exceeded for anti-tumor immunity or autoimmunity to 
be elicited [12]. In cancer, endogenous immunity against 
a particular tumor antigen is normally insufficient to 
overcome tumor-mediated immune suppression. The 
degree of stringency of tolerance for a specific antigen 
dictates whether a treatment strategy will raise immunity 
above this threshold. Thus, in response to vaccines incor-
porating numerous antigens such as whole cell vaccines, 
the critical thresholds of tolerance for each component 
antigen may differ. The key to effective vaccination is in 
activating the low-avidity, self-reactive T cells that have 
not been physically eliminated by peripheral tolerance to 
a level that can compensate for their relative weakness 
in recognizing tumor antigen [5]. Other antigen-inde-
pendent factors including the choice of adjuvant, vac-
cine delivery method, and location of the tumor will also 
affect the outcome of attempts to boost T cell activity to 
an immunogenic level.
Past immunotherapeutic approaches have provided 
examples where breaking peripheral tolerance against 
over-expressed self-antigens present in both normal and 
neoplastic tissue antigen led to off-target toxicity. A well-
studied example comes from paraneoplastic syndrome, 
a neurologic effect of cancer marked by loss of cerebel-
lar Purkinje cells and pancerebellar symptoms that often 
manifest themselves before the cancer is identified [13]. 
Some patients with gynecologic cancer present with anti-
Purkinje cell antibodies that are directed against tumor 
tissue as well as against the same antigens expressed in 
the cerebellum [14–16]. These antibodies have been 
proven to mediate cytotoxicity against cerebellar antigens 
[17]. Additionally, the neural antigen recoverin has been 
identified as an autoantigen in cancer-associated retin-
opathy (CAR), a paraneoplastic syndrome in which pho-
toreceptors are targeted, leading to vision loss in some 
cancer patients [18].
Melanoma is one type of cancer in which the specific-
ity of endogenous anti-tumor responses has been char-
acterized in patients and cross-reactivity with healthy 
tissues has been documented. In the absence of immuno-
therapy, melanoma patients can spontaneously develop 
potent CD8+ T cell responses to melanocyte differentia-
tion antigens. These T cell responses are associated with 
vitiligo, a cutaneous autoimmune disorder characterized 
by depigmentation of the skin, indicating the presence of 
potent anti-tumor immunity directed against antigens 
shared by normal melanocytes and melanoma cells [19]. 
Interestingly, the development of vitiligo in patients with 
melanoma is associated with an improved prognosis [20, 
21]. Studies have identified that the melanoma-specific 
CD8+ T cells are reactive against tyrosinase, a melano-
somal enzyme expressed during melanin biosynthesis 
in the skin [22]. Other targets of the immune response 
against melanoma were subsequently identified including 
TRP-1, TRP-2, and gp100, which are involved in melanin 
biosynthesis, and antigens like MART1/melan A that lack 
known function but are melanocyte-specific tissue dif-
ferentiation antigens [23–26]. In fact, studies have shown 
that CD8+ T cell reactivity against melanocyte-specific 
differentiation antigens was the dominant response, 
whereas CD8+ reactivity against tumor-specific muta-
tions was infrequent [27–30]. Hence, T cell reactivity 
against self-antigens can occur during naturally arising 
anti-tumor immunity in the absence of immunotherapy.
In melanoma, autoimmune sequelae resulting from 
immunotherapy appear to be increased in frequency 
and severity compared to those arising from natural 
immunity against tumors. Vitiligo has been frequently 
reported in response to immunotherapy including IL-2 
therapy, adoptive transfers of tumor-infiltrating lym-
phocytes, and other tumor vaccines [6, 31]. A condition 
mimicking uveitis, an autoimmune reaction in the reti-
nal pigment epithelium and the choroid of the eye, was 
reported in some melanoma patients undergoing immu-
notherapy with tumor-infiltrating lymphocytes plus 
IL-2, anti-CTLA-4 antibodies plus IL-2 with or without 
a gp100 vaccine [32–34]. Generally speaking, the more 
aggressive the immunotherapy regimen, the greater is 
the chance of autoimmunity resulting from activation of 
T cells specific for melanocyte differentiation antigens. 
It has been suggested that the incidence of autoimmune 
events, which included colitis, pruritis, dermatitis, hepa-
titis, hypophysitis and uveitis, were positively correlated 
with the dose of anti-CTLA-4 antibody administered 
[35]. To get a sense of the frequency of autoimmunity, a 
published study of 35 patients with metastatic melanoma 
undergoing a very aggressive treatment regimen consist-
ing of lympho-depleting chemotherapy and then tumor 
infiltrating lymphocytes plus high-dose IL-2, the results 
revealed that twelve patients developed vitiligo, three 
patients had uveitis, and two patients were diagnosed 
as having both conditions. Although vitiligo and uveitis 
appear to be common effects of melanoma immunother-
apy, these conditions are medically manageable, the latter 
complication being treatable by local steroid administra-
tion. Importantly however, other serious autoimmune 
manifestations resulting from melanoma immunotherapy 
have also been reported. In one study of 198 melanoma 
patients undergoing treatment with anti-CTLA-4 anti-
body, 21 % of the patients developed enterocolitis, requir-
ing high dose systemic corticosteroid treatment, and five 
patients developed perforations or required colectomy 
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[36]. Objective tumor response rates correlated with the 
autoimmune manifestations in the majority of patients. 
These examples demonstrate that autoreactive T cells 
do persist in the periphery and they can be awakened 
therapeutically as effectors with specificity for epitopes 
expressed by both tumors and healthy cells.
Immunological rationale for vaccination strategies 
targeting the tumor vasculature
Vaccination strategies directed against tumor-associated 
endothelium are designed to take advantage of both 
quantitative and qualitative differences between tumor 
endothelial cells and non-malignant endothelial cells. 
An ideal tumor endothelial antigen is overexpressed in 
tumors and poorly expressed or absent in peripheral tis-
sues. Given the high metabolic demands of tumors and 
their requirement for continued vascular development, 
tumor endothelial cells over-express an abundance of 
angiogenesis- and proliferation-associated molecules, in 
particular, numerous growth factors and their receptors. 
Putative vaccine targets that have been identified include 
tumor endothelial marker-1 (TEM1), vascular endothelial 
growth factor receptors 1 and 2, endoglin/CD105, basic 
fibroblast growth factor (bFGF) and its receptors, angi-
opoietin, and epidermal growth factor receptor (EGFR). 
While these antigens are over-expressed in tumor 
endothelium, they are also expressed to varying extents 
during physiological angiogenesis while being largely 
absent in quiescent endothelium of healthy adult tissues 
[37, 38]. In fact, systematic profiling of gene expression 
in tumor endothelium vs. healthy endothelium identified 
that the majority of tumor endothelium-associated genes 
could be detected in the angiogenic vessels of the ovaries, 
an indicator of physiological angiogenesis [38]. One nota-
ble exception is tumor endothelial marker 8 (TEM8), an 
integrin-like receptor that exhibits expressed restricted 
to tumors as well as human umbilical vein endothelial 
cells (HUVEC) where it is expressed during endothelial 
tube formation [38, 39]. Antigen profiling studies have 
also identified markers that are expressed on endothe-
lium of select tumor types but not others [37]. Overall, 
the thrust of these studies has been to identify antigens 
found in abundance in tumor endothelium of diverse 
tumor types, thereby allowing for broader vaccine appli-
cation, which also exhibit the lowest abundance or most 
restricted tissue distribution in non-malignant tissues.
Two general categories of tumor endothelial cell-
based vaccines have been evaluated; namely, vaccines 
against specific peptides/proteins and/or whole cell vac-
cines consisting of endothelial cell lysates. Ultimately, 
the choice of antigen is one of numerous variables that 
must be optimized, given that the effectiveness for elicit-
ing humoral and cell-mediated immunity against tumors 
is also affected by the mode of vaccine delivery (i.e. DNA, 
protein or peptide vaccines), the type of adjuvant, and the 
route(s) of vaccine administration [40]. A recent focus 
has been on clinical development of tumor endothelial 
cell-based vaccines consisting of whole cell lysates plus 
adjuvant stimulation for triggering anti-cancer immunity. 
By providing a myriad of antigens, polyvalent whole cell 
vaccines are believed to offer some advantages over mon-
ovalent (peptide) vaccines. Monovalent vaccines have 
potential drawbacks that include T cell epitope restric-
tion to particular MHC haplotypes, inadequate activa-
tion of innate immunity, and the risk of immunoselection 
of epitope-loss variants [41]. On the other hand, the fact 
that polyvalent vaccines contain abundant intracellular 
antigens ubiquitous to all mammalian cells has raised 
the possibility that adverse autoimmune reactions might 
occur.
When considering a tumor endothelial cell-based vac-
cine from a safety perspective, a primary question is 
whether the polyvalent nature of a cell-based vaccine 
confers an autoimmunity risk, considering the fact that an 
array of structurally and functionally conserved endothe-
lial cell antigens are present that are shared in common 
with healthy endothelium. As will be detailed below, the 
actual risk of autoimmunity has been low, as supported 
by numerous animal studies and preliminary clinical 
reports. The apparent safety of these vaccines may be 
attributable to the fact that only a finite antigenic compo-
nent of a cellular vaccine is processed and presented to T 
cells—the epitope selection is restricted. Moreover, a the-
ory has been put forth that self-reactive T cell responses 
arise against self-epitopes that are cryptic (i.e. previously 
hidden), a term that describes epitopes that are consid-
ered to be minor determinants, that are available in rela-
tively low amounts after antigen processing [42]. Notably, 
T cells specific for cryptic epitopes are able to escape 
tolerance and persist in the periphery where they pose 
little harm to healthy tissues; however, they possess the 
potential to become activated under immunogenic con-
ditions and when their cognate epitopes are available at 
higher concentrations [43]. In contrast, immunodomi-
nant epitopes are amply processed, allowing T cells that 
recognize them to be effectively deleted. If this theory is 
applicable, a cellular vaccine that provides sufficient anti-
gen and immunogenic signals may activate tumor-reac-
tive T cells directed against cryptic epitope with little risk 
of autoimmune manifestations elsewhere in the body.
In a study of a model self-antigen, it was demonstrated 
that exposure of antigen presenting cells to the cytokine 
IL-6 led to the processing and presentation of cryptic 
determinants of an antigen [44]. Display of cryptic deter-
minants has been described as a cornerstone for acti-
vation of self reactive T cells in autoimmunity [45] and 
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also been documented to occur in anti-tumor immunity 
[46]. Cryptic epitopes of self-antigens highly expressed 
by tumors have been demonstrated to be pivotal targets 
of therapy that result from qualitative and quantitative 
differences in antigen handling by APC [46]. IL-6 itself 
has a prominent role in tumor angiogenesis, upregulat-
ing VEGF expression [47]. Hyper-IL-6, an artificial fusion 
cytokine comprising IL-6 plus an artificial linker with 
the soluble IL-6 receptor, has been utilized as a compo-
nent of whole cell vaccines against cancers [48]. On this 
basis, the choice of adjuvant use for delivery of a cancer 
vaccine can affect the epitopes that are processed and 
presented by antigen presenting cells, perhaps unveiling 
cryptic epitopes for T cell recognition. Indeed, one study 
suggested that both endogenous and exogenous influ-
ences, as dictated by the tumor microenvironment and 
the choice of vaccine, can overcome the default response 
of immunological ignorance to cancer [49].
Safety of tumor endothelial cell‑based vaccines
Table 1 outlines vaccines directed against tumor endothe-
lium, specifically including protein/peptide vaccines that 
have been evaluated with respect to safety. The results 
demonstrate that, with the exception of one study, no 
effects were reported on wound healing and reproduc-
tion, two processes that involve endothelial cell prolif-
eration and angiogenesis. To date, these approaches have 
been largely experimental and conducted in animals, 
although clinical trials have tested vaccination against 
vascular endothelial growth factor in cancer patients 
[50, 51]. Before any definitive conclusions can be drawn, 
safety of individual peptide vaccines against tumor vascu-
lar targets should be evaluated much more extensively in 
a clinical setting.
Polyvalent vaccines comprised of tumor endothelial cell 
lysates that have been applied clinically have consisted of 
HUVEC and, more recently, a placental endothelial cell 
vaccines; ValloVax™. In the tumor milieu, the excessive 
release of angiogenic factors leads to over-expression of 
antigens that typify active and proliferating endothelium 
[38, 52–56]. Similarly, in both umbilical cord and pla-
centa, in the face of the continually increasing demands 
for blood supply for the developing fetus, endothelial cells 
derived from these tissues are highly proliferative and 
angiogenic. In fact, fetal tissues are believed to immuno-
logically resemble tumors, as first suggested by Dr. Val-
entin Govollo in the 1970s who noted the occurrence of 
immune cross-reactivity between placental trophoblast 
cells and lung cancer [57]. From an antigenic standpoint, 
the tumor endothelium is thought to more closely resem-
ble endothelium from early fetal development than nor-
mal adult endothelium.
HUVEC have been used in pilot studies to test the 
anti-angiogenic effects as well as the safety of vaccina-
tion in patients with malignant brain tumors and meta-
static colorectal cancer [58, 59]. In a published report 
where a total of 230 vaccinations were administered to 
a total of nine patients, MRI results showed partial or 
complete anti-tumor responses lasting for a minimum 
of 9  months in three of the patients with brain tumors 
[58]. Moreover, antibodies directed against HUVEC 
antigens were detected in eight out of total nine patients 
and HUVEC-specific CTL were detected in six of seven 
tested patients. No adverse events were reported with the 
exception of skin reactions at the vaccine injection site. In 
a related study where 352 vaccinations were performed 
in 17 patients with recurrent glioblastoma, reductions in 
tumor growth rates were observed and no adverse events 
were observed with the exception of skin reactions at the 
injection sites.
Case study: treatment of cancer patients 
with ValloVax™, a novel tumor endothelial vaccine
ValloVax™ is a tumor endothelial cell vaccine consisting of 
placenta-derived endothelial cells pretreated, serving as a 
more abundant source of cells than umbilical cord, that 
are pre-treated with interferon gamma to enhance immu-
nogenicity. In a previous pre-clinical study, we reported 
that ValloVax™ potently inhibited tumor growth in three 
histologically distinct animal models and also suppresses 
pulmonary metastasis subsequent to intravenous tumor 
administration [60]. In this report, we describe prelimi-
nary clinical safety and efficacy data, as measured on the 
basis of the ability of ValloVax™ immunization to elicit 
antibody response against well-established antigens that 
are over-expressed by tumor endothelial cells that are 
described in Table  2. Three patients with diverse types 
and stages of cancer that underwent treatment with Vall-
oVax™ at the Pan American Cancer Treatment Center, 
under the Regenerative Medicine Institute Institutional 
Review Board approval, and follow up visits in the time 
period between May 2015 and October 2015.
Patient 1 was a 55-year old male diagnosed with colon 
cancer and adjacent lymphadenopathy who had under-
gone colon resection and resection of extraperitoneal 
metastases. As per the standard protocol for ValloVax™ 
administration, patient 1 was treated with three sub-
cutaneous injections of ValloVax™ on days 0, 7 and 14 
and serum collection was performed pre-immunization 
and 12 and 22 weeks for detection of antibodies against 
tumor endothelial cell antigens in serum. The analy-
sis for detection of antibodies against tumor endothe-
lial antigens were conducted prior to immunization, 
and 4 and 10  weeks following immunization. Patient 
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antibody analyses were conducted using ELISA tech-
niques whereby plates were incubated in microwell plates 
with their respective capture proteins and dilutions of 
patient serum samples. The assay was performed using 
an OPD developing agent and optical density (OD) read-
ings at 490 nm.
Patient 2, a 48-year old female, presented with rectal 
ulcerated moderately differentiated adenocarcinoma and 
a previous history of diffuse large non-B cell non-Hodg-
kins lymphoma. The patient was also treated with three 
subcutaneous injections of ValloVax™ on days 0, 7 and 
14. Quantitation of antibodies against tumor endothelial 
antigens was performed using serum samples harvested 
at 10 and 16  weeks post-immunization to compare to 
pre-immunization serum.
Patient 3 was a 44-year old female with recurrent 
hemangioblastoma who previously underwent stereo-
tactic radiosurgery and was administered ValloVax™ on 
days 0, 7 and 14. Serum samples taken pre-immunization 
were compared to those taken at one time point that was 
7 weeks post-vaccination.
The antibody analysis data for the three patients 
treated with ValloVax™ are presented in Fig. 1. Antibody 
responses against each of the tumor endothelial antigens 
examined, namely VEGF-R1, VEGF-R2, endoglin, FGFR, 
CD51, CD61 and CD248 (TEM-1, endosialin), were 
detected in virtually all the patients immunized with 
the ValloVax™ placental vaccine. In all cases, ValloVax™ 
immunization increased the concentrations of antibodies 
against these targets over pre-immunization levels. While 
these preliminary data do not attest to clinical outcomes 
of cancer patients, these experiments do reveal a spe-
cific immunoglobulin response against tumor endothe-
lial antigens. As per Appendix 1, which comprises serum 
biochemistry panel results for these three patients for 
pre- and post-immunization time points, no abnormali-
ties were noted. Additionally, no adverse events were 
reported associated with ValloVax™ administration based 
on medical examination and post-treatment interviews.
Conclusions
Although tumors are comprised of self antigens that mir-
ror the antigens expressed in normal tissues, and the 
elimination of autoreactive T cells is an incomplete pro-
cess, the available evidence is in favor of the concept that 
anti-cancer immunity overlaps with but can be mecha-
nistically uncoupled from deleterious autoimmunity. In 
designing novel immunotherapeutic strategies, many 
of the mechanisms for self-tolerance and epitope selec-
tion inherent to the immune system can operate in favor 
Table 2 Tumor endothelial cell antigens investigated as targets of ValloVax™
Tumor endothelial target protein Role of antigen in tumor angiogenesis Refs
Vascular endothelial growth factor receptor‑1 (VEGFR‑1);  
fms‑like tyrosine kinase (flt)‑1
Receptor that binds VEGF with high affinity
Dominant receptor in the tumor microenvironment that is required 
for endothelial cell survival
[70, 71]
Vascular endothelial growth factor receptor‑2 (VEGFR2);  
Flk‑1, KDR
Also known as FLK‑1 and KDR
Binds to VEGF and is considered the most important receptor with 
regard to tumor angiogenesis
Expressed on proliferating endothelium
Low expression on healthy vascular endothelium
[62, 72]
Endoglin/CD105 Selectively expressed by endothelial cells undergoing vasculogen‑
esis, angiogenesis, and inflammation
Promotes endothelial cell proliferation, migration, and tube forma‑
tion during early development and in tumors
[73–78]
Fibroblast growth factor receptor (FGFR) Bind to fibroblast growth factor family members, having diverse 
roles in organogenesis, proliferation, pro‑survival cell signaling 
and cellular migration
FGF/FGFR system contributes to both adult angiogenesis and 
tumor angiogenesis
FGFR signaling is implicated in escape of tumor vasculature from 
VEGF inhibitor treatment
[61, 79–82]
Integrin αvβ3; CD51/CD61 An extracellular matrix adhesion receptor that coordinates endothe‑
lial cell responses during angiogenesis
Expressed in neo‑angiogenic vessels; therefore, it is upregulated in 
the vasculature of solid tumors, while expression is low in quies‑
cent vasculature
[83–87]
Tumor endothelial marker 1 (TEM1); endosialin or CD248 One of the most abundantly expressed proteins on tumor vascula‑
ture and tumor stroma of human tumors
Expression is variable among tumor types; however, this protein can 
reportedly be expressed on endothelial cells, pericytes, and/or 
fibroblasts of human and animal tumors
[67, 88–93]
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Fig. 1 Analysis of antibodies against tumor endothelial antigens in three patients treated with ValloVax™. Antibodies against each of the antigens 
indicated were detected in dilutions of patient serum samples by ELISA and OD 490 readings were compared for pre‑immunization, and time 
points (T1 and T2) following immunization with ValloVax™
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of selective anti-tumor immunity while minimizing the 
scope and severity of off-target toxicity. Novel cellular 
vaccines, including a placental endothelial vaccine, Vallo-
Vax™, have shown clinical promise in terms of safety and 
can hopefully be used to efficaciously guide the immune 
response toward destruction of pathological endothelial 
cells that are required for tumor growth and survival. 
Preliminary clinical data demonstrate that vaccination 
of cancer patients with ValloVax™ is not only well-toler-
ated but also elicits humoral immunity against an array 
of tumor endothelial cell-associated antigens with known 
pathological roles in tumor angiogenesis.
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Appendix 1
See Tables 3, 4 and 5.
Table 3 Patient 1
Test Pre-immunization Time point 1 Time point 2 Normal ranges
Bicarbonate (total) (mEq/L) 22 24 20 18–30
Calcium (total) (mg/dL) 10 10 11 9–11
Chloride (mEq/L) 99 101 103 98–106
Magnesium (mg/dL) 3.2 3.1 3.5 1.8–3.6
Phosphorus (mg/dL) 3.1 3.5 3.9 3–4.5
Sodium (mEq/L) 145 138 135 135–147
Alkaline Phosphatase (U/L) 140 79 74 50–160
Amylase (U/L) 122 119 110 53–123
Creatine kinase (U/L) 101 115 99 38–174 (males)
96–140 (females)
Lipase (U/L) 34 58 27 10–150
ALT (GPT) (U/L) 11 25 14 0–30
AST (GOP) (U/L) 39 24 12 0–40
Albumin (g/dL) 3.8 3.5 4.8 3.5–5.5
Bilirubin (total) (mg/dL) .3 .4 .2 <1.0
Cholesterol (mg/dL) 202 183 222 <225
Creatinine (mg/dL) 1.7 1.5 1.1 1.0–2.0
Globulin (g/dL) 1.5 1.7 1.8 1.5–3.5
Glucose (mg/dL) 132 110 93 80–120
Protein (total) (g/dL) 5.8 6.5 6.1 6.3–8.0
Triglycerides (mg/dL) 226 221 232 40–200
Urea (mg/dL) 22 27 24 20–40
Uric acid (mg/dL) 2.5 2.2 2.1 2.0–4.0
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Table 4 Patient 2
Test Pre-immunization Time point 1 Time point 2 Normal ranges
Bicarbonate (total) (mEq/L) 28 24 27 18–30
Calcium (total) (mg/dL) 11 10 10 9–11
Chloride (mEq/L) 105 101 102 98–106
Magnesium (mg/dL) 3.1 2.4 2.1 1.8–3.6
Phosphorus (mg/dL) 3.3 3.2 3.1 3–4.5
Sodium (mEq/L) 138 143 141 135–147
Alkaline Phosphatase (U/L) 154 144 164 50–160
Amylase (U/L) 104 121 120 53–123
Creatine kinase (U/L) 131 79 74 38–174 (males)
96–140 (females)
Lipase (U/L) 75 89 125 10–150
ALT (GPT) (U/L) 25 29 21 0–30
AST (GOP) (U/L) 13 36 36 0–40
Albumin (g/dL) 4.3 5.3 4.2 3.5–5.5
Bilirubin (total) (mg/dL) .1 .2 .3 <1.0
Cholesterol (mg/dL) 95 201 199 <225
Creatinine (mg/dL) 1.6 1.7 1.5 1.0–2.0
Globulin (g/dL) 1.8 3.9 3.2 1.5–3.5
Glucose (mg/dL) 94 102 108 80–120
Protein (total) (g/dL) 7.3 8.4 7.5 6.3–8.0
Triglycerides (mg/dL) 185 174 186 40–200
Urea (mg/dL) 38 40 23 20–40
Uric acid (mg/dL) 3.1 3.9 3.4 2.0–4.0
Table 5 Patient 3
Test Pre-immunization Time point 1 Normal ranges
Bicarbonate (total) (mEq/L) 19 20 18–30
Calcium (total) (mg/dL) 12 11 9–11
Chloride (mEq/L) 105 104 98–106
Magnesium (mg/dL) 2.4 2.7 1.8–3.6
Phosphorus (mg/dL) 3.1 3.1 3–4.5
Sodium (mEq/L) 149 151 135–147
Alkaline Phosphatase (U/L) 111 159 50–160
Amylase (U/L) 108 80 53–123
Creatine kinase (U/L) 112 142 38–174 (males)
96–140 (females)
Lipase (U/L) 101 125 10–150
ALT (GPT) (U/L) 53 42 0–30
AST (GOP) (U/L) 84 42 0–40
Albumin (g/dL) 3.3 4.3 3.5–5.5
Bilirubin (total) (mg/dL) .6 .7 <1.0
Cholesterol (mg/dL) 102 124 <225
Creatinine (mg/dL) 1.3 1.8 1.0–2.0
Globulin (g/dL) 2.4 3.2 1.5–3.5
Glucose (mg/dL) 114 101 80–120
Protein (total) (g/dL) 7.4 5.3 6.3–8.0
Triglycerides (mg/dL) 101 121 40–200
Urea (mg/dL) 29 32 20–40
Uric acid (mg/dL) 2.5 2.1 2.0–4.0
Page 11 of 12Wagner et al. J Transl Med  (2016) 14:90 
Received: 12 December 2015   Accepted: 30 March 2016
References
 1. HoptionCann SA, van Netten JP, van Netten C. Dr William Coley and 
tumour regression: a place in history or in the future. Postgrad Med J. 
2003;79(938):672–80.
 2. Monjazeb AM, et al. The role of antigen‑specific and non‑specific immu‑
notherapy in the treatment of cancer. J Immunotoxicol. 2012;9(3):248–58.
 3. Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where 
are we? Vaccines (Basel). 2015;3(2):344–72.
 4. Miska J, Devarajan P, Chen Z. The immunological identity of tumor: self 
implications. Oncoimmunology. 2013;2(4):e23794.
 5. Gilboa E. The makings of a tumor rejection antigen. Immunity. 
1999;11(3):263–70.
 6. Gyorki DE, et al. The delicate balance of melanoma immunotherapy. Clin 
Transl Immunol. 2013;2(8):e5.
 7. Dudley AC. Tumor endothelial cells. Cold Spring Harb Perspect Med. 
2012;2(3):a006536.
 8. Motz GT, et al. Tumor endothelium FasL establishes a selective immune 
barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–15.
 9. Lund AW, et al. VEGF‑C promotes immune tolerance in B16 melanomas 
and cross‑presentation of tumor antigen by lymph node lymphatics. Cell 
Rep. 2012;1(3):191–9.
 10. Gabrilovich DI, et al. Production of vascular endothelial growth factor by 
human tumors inhibits the functional maturation of dendritic cells. Nat 
Med. 1996;2(10):1096–103.
 11. Folkman J. Fighting cancer by attacking its blood supply. Sci Am. 
1996;275(3):150–4.
 12. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad 
Sci USA. 1999;96(10):5340–2.
 13. Brain L, Wilkinson M. Subacute cerebellar degeneration associated with 
neoplasms. Brain. 1965;88(3):465–78.
 14. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in 
patients with paraneoplastic cerebellar degeneration and ovarian carci‑
noma. Ann Neurol. 1983;14(6):609–13.
 15. Greenlee JE, et al. Association of anti‑Yo (type I) antibody with para‑
neoplastic cerebellar degeneration in the setting of transitional cell 
carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall 
in antibody titers following tumor removal. Ann Neurol. 1999;45(6):805–9.
 16. Furneaux HM, et al. Selective expression of Purkinje‑cell antigens in 
tumor tissue from patients with paraneoplastic cerebellar degeneration. 
N Engl J Med. 1990;322(26):1844–51.
 17. Greenlee JE, et al. Anti‑Yo antibody uptake and interaction with its 
intracellular target antigen causes Purkinje cell death in rat cerebel‑
lar slice cultures: a possible mechanism for paraneoplastic cerebellar 
degeneration in humans with gynecological or breast cancers. PLoS One. 
2015;10(4):e0123446.
 18. Polans AS, et al. Recoverin, a photoreceptor‑specific calcium‑binding 
protein, is expressed by the tumor of a patient with cancer‑associated 
retinopathy. Proc Natl Acad Sci USA. 1995;92(20):9176–80.
 19. Le Gal FA, et al. Direct evidence to support the role of antigen‑specific 
CD8(+) T cells in melanoma‑associated vitiligo. J Invest Dermatol. 
2001;117(6):1464–70.
 20. Nordlund JJ, et al. Vitiligo in patients with metastatic melanoma: a good 
prognostic sign. J Am Acad Dermatol. 1983;9(5):689–96.
 21. Quaglino P, et al. Vitiligo is an independent favourable prognostic 
factor in stage III and IV metastatic melanoma patients: results from a 
single‑institution hospital‑based observational cohort study. Ann Oncol. 
2010;21(2):409–14.
 22. Coulie PG, et al. A new gene coding for a differentiation antigen recog‑
nized by autologous cytolytic T lymphocytes on HLA‑A2 melanomas. J 
Exp Med. 1994;180(1):35–42.
 23. Cox AL, et al. Identification of a peptide recognized by five melanoma‑
specific human cytotoxic T cell lines. Science. 1994;264(5159):716–9.
 24. Kawakami Y, et al. Identification of a human melanoma antigen recog‑
nized by tumor‑infiltrating lymphocytes associated with in vivo tumor 
rejection. Proc Natl Acad Sci USA. 1994;91(14):6458–62.
 25. Bakker AB, et al. Melanocyte lineage‑specific antigen gp100 is recognized 
by melanoma‑derived tumor‑infiltrating lymphocytes. J Exp Med. 
1994;179(3):1005–9.
 26. Wang RF, et al. Identification of TRP‑2 as a human tumor antigen recog‑
nized by cytotoxic T lymphocytes. J Exp Med. 1996;184(6):2207–16.
 27. Coulie PG, et al. A mutated intron sequence codes for an antigenic pep‑
tide recognized by cytolytic T lymphocytes on a human melanoma. Proc 
Natl Acad Sci USA. 1995;92(17):7976–80.
 28. Wolfel T, et al. A p16INK4a‑insensitive CDK4 mutant targeted by cytolytic 
T lymphocytes in a human melanoma. Science. 1995;269(5228):1281–4.
 29. Robbins PF, et al. A mutated beta‑catenin gene encodes a melanoma‑
specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 
1996;183(3):1185–92.
 30. Topalian SL, et al. Melanoma‑specific CD4+ T cells recognize nonmutated 
HLA‑DR‑restricted tyrosinase epitopes. J Exp Med. 1996;183(5):1965–71.
 31. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal 
tissue antigens can be targets for cancer immunotherapy. J Immunother 
Emphasis Tumor Immunol. 1996;19(1):81–4.
 32. Dudley ME, et al. Cancer regression and autoimmunity in patients 
after clonal repopulation with antitumor lymphocytes. Science. 
2002;298(5594):850–4.
 33. Maker AV, et al. Tumor regression and autoimmunity in patients treated 
with cytotoxic T lymphocyte‑associated antigen 4 blockade and interleu‑
kin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005–16.
 34. Robinson MR, et al. Cytotoxic T lymphocyte‑associated antigen 4 
blockade in patients with metastatic melanoma: a new cause of uveitis. J 
Immunother. 2004;27(6):478–9.
 35. Ku GY, et al. Single‑institution experience with ipilimumab in advanced 
melanoma patients in the compassionate use setting: lymphocyte count 
after 2 doses correlates with survival. Cancer. 2010;116(7):1767–75.
 36. Beck KE, et al. Enterocolitis in patients with cancer after antibody 
blockade of cytotoxic T‑lymphocyte‑associated antigen 4. J Clin Oncol. 
2006;24(15):2283–9.
 37. Seaman S, et al. Genes that distinguish physiological and pathological 
angiogenesis. Cancer Cell. 2007;11(6):539–54.
 38. St Croix B, et al. Genes expressed in human tumor endothelium. Science. 
2000;289(5482):1197–202.
 39. Nanda A, et al. TEM8 interacts with the cleaved C5 domain of collagen 
alpha 3(VI). Cancer Res. 2004;64(3):817–20.
 40. Hou J, Tian L, Wei Y. Cancer immunotherapy of targeting angiogenesis. 
Cell Mol Immunol. 2004;1(3):161–6.
 41. Keenan BP, Jaffee EM. Whole cell vaccines—past progress and future 
strategies. Semin Oncol. 2012;39(3):276–86.
 42. Sercarz EE, et al. Dominance and crypticity of T cell antigenic determi‑
nants. Annu Rev Immunol. 1993;11:729–66.
 43. Gammon G, Sercarz E. How some T cells escape tolerance induction. 
Nature. 1989;342(6246):183–5.
 44. Drakesmith H, et al. In vivo priming of T cells against cryptic determinants 
by dendritic cells exposed to interleukin 6 and native antigen. Proc Natl 
Acad Sci USA. 1998;95(25):14903–8.
 45. Moudgil KD, Sercarz EE. Crypticity of self antigenic determinants is the 
cornerstone of a theory of autoimmunity. Discov Med. 2005;5(28):378–82.
 46. Fischer E, et al. Cryptic epitopes induce high‑titer humoral immune 
response in patients with cancer. J Immunol. 2010;185(5):3095–102.
 47. Huang SP, et al. Interleukin‑6 increases vascular endothelial growth 
factor and angiogenesis in gastric carcinoma. J Biomed Sci. 
2004;11(4):517–27.
 48. Wysocki PJ, et al. Gene‑modified tumor vaccine secreting a designer 
cytokine hyper‑interleukin‑6 is an effective therapy in mice bearing 
orthotopic renal cell cancer. Cancer Gene Ther. 2010;17(7):465–75.
 49. Lally KM, et al. Unmasking cryptic epitopes after loss of immunodomi‑
nant tumor antigen expression through epitope spreading. Int J Cancer. 
2001;93(6):841–7.
 50. Gavilondo JV, et al. Specific active immunotherapy with a VEGF 
vaccine in patients with advanced solid tumors. Results of the 
CENTAURO antigen dose escalation phase I clinical trial. Vaccine. 
2014;32(19):2241–50.
 51. Miyazawa M, et al. Phase I clinical trial using peptide vaccine for human 
vascular endothelial growth factor receptor 2 in combination with 
gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 
2010;101(2):433–9.
Page 12 of 12Wagner et al. J Transl Med  (2016) 14:90 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 52. Khodarev NN, et al. Tumour‑endothelium interactions in co‑culture: coor‑
dinated changes of gene expression profiles and phenotypic properties 
of endothelial cells. J Cell Sci. 2003;116(Pt 6):1013–22.
 53. Bhati R, et al. Molecular characterization of human breast tumor vascular 
cells. Am J Pathol. 2008;172(5):1381–90.
 54. Hellebrekers DM, et al. Epigenetic regulation of tumor endothelial cell 
anergy: silencing of intercellular adhesion molecule‑1 by histone modifi‑
cations. Cancer Res. 2006;66(22):10770–7.
 55. Hellebrekers DM, et al. Identification of epigenetically silenced genes in 
tumor endothelial cells. Cancer Res. 2007;67(9):4138–48.
 56. Lokhov PG, Balashova EE. Design of universal cancer vaccines using natu‑
ral tumor vessel‑specific antigens (SANTAVAC). Hum Vaccin Immunother. 
2015;11(3):689–98.
 57. Harandi A. Immunoplacental therapy, a potential multi‑epitope cancer 
vaccine. Med Hypotheses. 2006;66(6):1182–7.
 58. Okaji Y, et al. Pilot study of anti‑angiogenic vaccine using fixed whole 
endothelium in patients with progressive malignancy after failure of 
conventional therapy. Eur J Cancer. 2008;44(3):383–90.
 59. Tanaka M, et al. Human umbilical vein endothelial cell vaccine therapy in 
patients with recurrent glioblastoma. Cancer Sci. 2013;104(2):200–5.
 60. Ichim TE, et al. Induction of tumor inhibitory anti‑angiogenic response 
through immunization with interferon Gamma primed placental 
endothelial cells: ValloVax. J Transl Med. 2015;13:90.
 61. Plum SM, et al. Generation of a specific immunological response to FGF‑2 
does not affect wound healing or reproduction. Immunopharmacol 
Immunotoxicol. 2004;26(1):29–41.
 62. Niethammer AG, et al. A DNA vaccine against VEGF receptor 2 
prevents effective angiogenesis and inhibits tumor growth. Nat Med. 
2002;8(12):1369–75.
 63. Seavey MM, et al. An anti‑vascular endothelial growth factor receptor 
2/fetal liver kinase‑1 Listeria monocytogenes anti‑angiogenesis cancer 
vaccine for the treatment of primary and metastatic Her‑2/neu + breast 
tumors in a mouse model. J Immunol. 2009;182(9):5537–46.
 64. Morera Y, et al. Immunogenicity and some safety features of a VEGF‑
based cancer therapeutic vaccine in rats, rabbits and non‑human 
primates. Vaccine. 2010;28(19):3453–61.
 65. Jarosz M, et al. Therapeutic antitumor potential of endoglin‑based 
DNA vaccine combined with immunomodulatory agents. Gene Ther. 
2013;20(3):262–73.
 66. Xiang R, et al. A DNA vaccine targeting survivin combines apoptosis 
with suppression of angiogenesis in lung tumor eradication. Cancer Res. 
2005;65(2):553–61.
 67. Facciponte JG, et al. Tumor endothelial marker 1‑specific DNA vaccina‑
tion targets tumor vasculature. J Clin Invest. 2014;124(4):1497–511.
 68. Haller BK, et al. Therapeutic efficacy of a DNA vaccine targeting the 
endothelial tip cell antigen delta‑like ligand 4 in mammary carcinoma. 
Oncogene. 2010;29(30):4276–86.
 69. Fernandez Lorente A, et al. Effect of blockade of the EGF system on 
wound healing in patients vaccinated with CIMAvax(R) EGF. World J Surg 
Oncol. 2013;11:275.
 70. Zhang Z, et al. VEGF‑dependent tumor angiogenesis requires inverse 
and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 
2010;17(3):499–512.
 71. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 
2013;13(12):871–82.
 72. Chatterjee S, et al. Tumor VEGF:VEGFR2 autocrine feed‑forward loop trig‑
gers angiogenesis in lung cancer. J Clin Invest. 2013;123(4):1732–40.
 73. Basilio‑de‑Oliveira RP, Pannain VL. Prognostic angiogenic markers (endog‑
lin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal 
stromal tumors. World J Gastroenterol. 2015;21(22):6924–30.
 74. Anderberg C, et al. Deficiency for endoglin in tumor vasculature 
weakens the endothelial barrier to metastatic dissemination. J Exp Med. 
2013;210(3):563–79.
 75. Jonker L, Arthur HM. Endoglin expression in early development 
is associated with vasculogenesis and angiogenesis. Mech Dev. 
2002;110(1–2):193–6.
 76. Torsney E, et al. Mouse model for hereditary hemorrhagic telangiectasia 
has a generalized vascular abnormality. Circulation. 2003;107(12):1653–7.
 77. Lebrin F, et al. Endoglin promotes endothelial cell proliferation and TGF‑
beta/ALK1 signal transduction. EMBO J. 2004;23(20):4018–28.
 78. Jerkic M, et al. Reduced angiogenic responses in adult endoglin heterozy‑
gous mice. Cardiovasc Res. 2006;69(4):845–54.
 79. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR‑mediated carcinogen‑
esis. Biochim Biophys Acta. 2012;1823(4):850–60.
 80. Casanovas O, et al. Drug resistance by evasion of antiangiogenic target‑
ing of VEGF signaling in late‑stage pancreatic islet tumors. Cancer Cell. 
2005;8(4):299–309.
 81. Turner N, Grose R. Fibroblast growth factor signalling: from development 
to cancer. Nat Rev Cancer. 2010;10(2):116–29.
 82. Fons P, et al. Tumor vasculature is regulated by FGF/FGFR signaling‑
mediated angiogenesis and bone marrow‑derived cell recruitment: this 
mechanism is inhibited by SSR128129E, the first allosteric antagonist of 
FGFRs. J Cell Physiol. 2015;230(1):43–51.
 83. Davis PJ, et al. Nanotetrac targets integrin alphavbeta3 on tumor cells to 
disorder cell defense pathways and block angiogenesis. Onco Targets 
Ther. 2014;7:1619–24.
 84. Silva R, et al. Integrins: the keys to unlocking angiogenesis. Arterioscler 
Thromb Vasc Biol. 2008;28(10):1703–13.
 85. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v 
beta 3 for angiogenesis. Science. 1994;264(5158):569–71.
 86. Brooks PC, et al. Integrin alpha v beta 3 antagonists promote tumor 
regression by inducing apoptosis of angiogenic blood vessels. Cell. 
1994;79(7):1157–64.
 87. Hariharan S, et al. Assessment of the biological and pharmacological 
effects of the alpha nu beta3 and alpha nu beta5 integrin receptor 
antagonist, cilengitide (EMD 121974), in patients with advanced solid 
tumors. Ann Oncol. 2007;18(8):1400–7.
 88. MacFadyen JR, et al. Endosialin (TEM1, CD248) is a marker of stromal 
fibroblasts and is not selectively expressed on tumour endothelium. FEBS 
Lett. 2005;579(12):2569–75.
 89. Christian S, et al. Endosialin (Tem1) is a marker of tumor‑associated 
myofibroblasts and tumor vessel‑associated mural cells. Am J Pathol. 
2008;172(2):486–94.
 90. Carson‑Walter EB, et al. Characterization of TEM1/endosialin in human 
and murine brain tumors. BMC Cancer. 2009;9:417.
 91. Brady J, et al. Human endosialin (tumor endothelial marker 1) is 
abundantly expressed in highly malignant and invasive brain tumors. J 
Neuropathol Exp Neurol. 2004;63(12):1274–83.
 92. Rouleau C, et al. Endosialin protein expression and therapeutic target 
potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer 
Res. 2008;14(22):7223–36.
 93. Bagley RG. Endosialin: from vascular target to biomarker for human 
sarcomas. Biomark Med. 2009;3(5):589–604.
